Investor directory

Atricure

AtriCure, Inc. is a medical device company specializing in the development, manufacture, and sale of surgical devices for the ablation of cardiac tissue. Founded in 2000 and headquartered in Mason, Ohio, AtriCure's product offerings include the Isolator Synergy and Isolator Synergy Access clamps for treating persistent atrial fibrillation, the EPi-Sense guided coagulation system, and the COBRA Fusion surgical ablation system. The company also provides multifunctional tools for cardiac evaluation and ablation, cryoablation systems, and instruments for cardiac surgeries. Its innovative solutions are designed to support minimally invasive cardiac and thoracic surgeries, addressing various conditions such as atrial fibrillation and postoperative pain management. AtriCure distributes its products through a combination of independent distributors and direct sales personnel, primarily focusing on the U.S. market.

Top Stages

Acquisition
http://atricure.com
https://app.dealroom.co/companies/atricure
https://crunchbase.com/organization/atricure
https://facebook.com/atricure
https://linkedin.com/company/atricure
https://twitter.com/atricure
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=901985

3 past transactions

SentreHEART

Acquisition in 2019
SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

nContact Surgical

Acquisition in 2015
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Estech

Acquisition in 2013
Estech is a privately held medical device manufacturing and distribution company based in San Ramon, California. Founded in 1996 by Arthur and Raymond Bertolero, the company focuses on developing and marketing medical devices and disposables that facilitate both traditional and minimally invasive cardiac surgical procedures. Estech has established a global distribution network and is recognized for attracting skilled professionals in the medical device sector. The company's commitment to innovation and quality has enabled it to achieve sustained success in a competitive industry, reflecting the dedication of its team across all departments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.